Division of Pulmonary and Critical Care Medicine and
Kidney Research Institute, Division of Nephrology, Department of Medicine, University of Washington, Seattle, Washington; and.
J Am Soc Nephrol. 2018 Nov;29(11):2713-2721. doi: 10.1681/ASN.2018070719. Epub 2018 Oct 4.
TNF receptor-1 (TNFR-1), which plays a causative role in endothelial cell dysfunction and inflammation, is expressed on the cell surface in glomerular and peritubular capillary endothelium of the kidneys. Higher soluble TNF receptor-1 (sTNFR-1) concentrations are associated with kidney disease progression among persons with established diabetic kidney disease. However, no studies have assessed sTNFR-1's role in long-term kidney function changes in a multiethnic population without cardiovascular disease at baseline.
We tested associations between baseline sTNFR-1 concentrations and 10-year decline in eGFR (incident ≥40% decline and annual proportional decline) among 2548 participants in the Multi-Ethnic Study of Atherosclerosis (MESA), a prospective cohort study. Serum creatinine concentrations were determined at enrollment and study years 3, 5, and 10.
Mean age of participants was 61 years old, 53% were women, and mean baseline eGFR was 79 ml/min per 1.73 m. Serum sTNFR-1 was inversely associated with baseline eGFR. Over median follow-up of 9.3 years, 110 participants developed ≥40% decline in eGFR; each SD higher concentration of sTNFR1 was associated with higher risk of 40% eGFR decline (adjusted hazard ratio, 1.43; 95% confidence interval [95% CI], 1.16 to 1.77; <0.001). The highest sTNFR-1 tertile was associated with adjusted annualized decline in eGFR of 1.94% (95% CI, 1.79 to 2.09). Associations persisted across subgroups defined by demographics, hypertension, diabetes, and baseline CKD status.
Elevated serum sTNFR-1 concentrations are associated with faster declines in eGFR over the course of a decade in a multiethnic population, independent of previously known risk factors for kidney disease progression.
TNF 受体-1(TNFR-1)在血管内皮细胞功能障碍和炎症中起因果作用,在肾脏的肾小球和肾小管毛细血管内皮细胞的细胞表面表达。在已确诊的糖尿病肾病患者中,较高的可溶性 TNF 受体-1(sTNFR-1)浓度与肾脏疾病进展相关。然而,在基线时无心血管疾病的多民族人群中,尚无研究评估 sTNFR-1 在长期肾功能变化中的作用。
我们在多民族动脉粥样硬化研究(MESA)的 2548 名参与者中,检测了基线 sTNFR-1 浓度与 eGFR 10 年下降(新发≥40%下降和年比例下降)之间的关联,这是一项前瞻性队列研究。在入组时以及研究第 3、5 和 10 年测定血清肌酐浓度。
参与者的平均年龄为 61 岁,53%为女性,平均基线 eGFR 为 79ml/min per 1.73m。血清 sTNFR-1 与基线 eGFR 呈负相关。在中位随访 9.3 年期间,有 110 名参与者出现 eGFR 下降≥40%;sTNFR1 每增加一个标准差,发生 40%eGFR 下降的风险就会增加(调整后的危险比,1.43;95%置信区间[95%CI],1.16 至 1.77;<0.001)。sTNFR-1 的最高三分位数与 eGFR 的调整后年化下降率为 1.94%(95%CI,1.79 至 2.09)相关。这些关联在按人口统计学、高血压、糖尿病和基线 CKD 状态定义的亚组中仍然存在。
在多民族人群中,血清 sTNFR-1 浓度升高与 eGFR 在十年内的快速下降相关,独立于已知的肾脏疾病进展风险因素。